Compare Biogen Inc (BIIB) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs New York Times Co — how do they compare? Biogen Inc trades at $191.26 (market cap $28.34B), while New York Times Co trades at $73.02 (market cap $11.81B). The key difference: Biogen Inc is far larger — about 2.4× New York Times Co's market cap, and New York Times Co pays a 1.26% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | NYT | |
|---|---|---|
Market Cap | $28.34B | $11.81B |
Sector | Health | Media |
52-Week High | $216.63 | $85.86 |
52-Week Low | $122.68 | $51.43 |
Enterprise Value | $30.62B | $11.21B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
The New York Times (NYT) stock trades at $75.04, up 0.11% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with revenue growth from $2.3B in 2022 to $2.8B in 2025 and net income margin improving to 12.17%. Recent earnings beats and a 29.41% analyst buy rating support positive sentiment, though legal and regulatory pressures from ongoing subpoenas and copyright disputes with OpenAI present near-term risks.
Outlook remains cautiously optimistic with a consensus price target of $78.00, offering ~4% upside. Investment opportunities include consistent earnings growth and defensive stock characteristics amid market volatility. Key risks involve legal overhangs from government subpoenas and AI copyright litigation, which could impact operational focus and financial performance if prolonged.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
